Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical study evaluating the combination of Intismeran Autogene (V940) and pembrolizumab (MK-3475) for malignant melanoma. The trial status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Intismeran Autogene (V940)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Melanoma | Phase 2 | Status: RECRUITING